Last updated: 2026-09-09 04:53:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
UroGen Pharma Ltd. (URGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $43.87, with a market capitalization of $2.16B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $15.86 to $53.46. This page covers its latest market performance, valuation, price trends and company information.
$2.16B | |
$43.24 | |
$69.57 | |
$3.42 | |
$44.09 | |
340.78K | |
815.99K | |
-- | |
$53.46 | |
$15.86 | |
-- | |
-- |
UroGen Pharma Ltd. (URGN) last closed at $44.09 as of 2026-09-08 23:31:00, unchanged from the previous close of $44.09.
During the latest regular trading session, URGN traded between $3.42 and $69.57, with a volume of 340.78K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, UroGen Pharma Ltd. (URGN) moved from $45.50 to $43.87, representing a decline of 3.59% ($1.63).
The stock traded between $42.00 and $53.46 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 657.64 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 74.5%
URGN is currently trading at $43.87, placing it 74.5% of the way from its 52-week low of $15.86 to its 52-week high of $53.46. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 291 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of UroGen Pharma Ltd. (URGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.